A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population

Show other versions (1)

Certolizumab pegol (CZP) is a PEGylated Fc-free tumor necrosis factor (TNF) inhibitor antibody approved for use in the treatment of rheumatoid arthritis (RA), Crohn’s disease, psoriatic arthritis, axial spondyloarthritis and psoriasis. In a clinical trial of patients with severe RA, CZP improved dis...

Full description

Bibliographic Details
Main Authors: Ian R. White, Sarah E. Kleinstein, Christophe Praet, Chris Chamberlain, Duncan McHale, Jessica M. Maia, Pingxing Xie, David B. Goldstein, Thomas J. Urban, Patrick R. Shea
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004786/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004786/?tool=EBI

Similar Items